Abstract:Ian JY Wee, 1 Fiona NN Moe, 1 Rehena Sultana, 2 Reiko WT Ang, 1 Pearly PS Quek, 3 Brian Kim Poh Goh, 1 Chung Yip Chan, 1 Peng Chung Cheow, 1 Alexander YF Chung, 1 Prema Raj Jeyaraj, 1 Ye Xin Koh, 1 Peter OP Mack, 1 London Lucien PJ Ooi, 1 Ek Khoon Tan, 1 Jin Yao Teo, 1 Juinn Huar Kam, 1 Jacelyn SS Chua, 1 Ashley WY Ng, 1 Jade SQ Goh, 1 Pierce KH Chow 1, 4 1 Department of Hepatopancreatobiliary and Transplantation Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore; 2 Center of Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore; 3 Ministry of Health Holdings, Singapore, Singapore; 4 Surgery Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore Correspondence: Pierce KH Chow, Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, 11 Hospital Drive, Singapore, 169610, Singapore, Tel +65 6576 2151, Email Objective: We aimed to prognosticate survival after surgical resection of HCC stratified by stage with amalgamation of the modified Barcelona Clinic Liver Cancer (BCLC) staging system and location of tumour. Methods: This single-institutional retrospective cohort study included patients with HCC who underwent surgical resection between 1st January 2000 to 30th June 2016. Participants were divided into 6 different subgroups: A-u) Within MC with Unilobar lesions; A-b) Within MC + Bilobar lesions; B1-u) Out of MC + within Up-To-7 + Unilobar lesions; B1-b) Out of MC + within Up-to-7 + Bilobar lesions; B2-u) Out of MC + Out of Up-To-7 + Unilobar lesions; B2-b) Out of MC + Out of Up-To-7 + Bilobar lesions. A separate survival analysis was conducted for solitary HCC lesions according to three subgroups: A-S (Within MC); B1-S (Out of MC + within Up-To-7); B2-S (Out of MC + out of Up-To-7). Results: A total of 794 of 1043 patients with surgical resection for HCC were analysed. Groups A-u (64.6%), A-b (58.4%) and B1-u (56.2%) had 5-year cumulative overall survival (OS) rates above 50% after surgical resection and median OS exceeding 60 months (P = 0.0001). The 5-year cumulative recurrence-free survival rates (RFS) were 40.4% (group A-u), 38.2% (group A-b), 36.3% (group B1-u), 24.6% (group B2-u), and 7.3% (group B2-b)(P=0.0001). For solitary lesions, the 5-year OS for the subgroups were A-S (65.1%), B1-S (56.0%) and B2-S (47.1%) (P = 0.0003). Compared to A-S, there was also a significant trend towards relatively poorer OS as the lesion sizes increased in B1-S (HR 1.46, 95% CI 1.03– 2.08) and B2-S (HR 1.65, 95% CI 1.25– 2.18). Conclusion: We adopted a novel approach combining the modified BCLC B sub-classification and dispersion of tumour to show that surgical resection in intermediate stage HCC can be robustly prognosticated. We found that size prognosticates resection outcomes in solitary tumours. Keywords: hepatocellular carcinoma, surgical resection, Barcelona clinic liver cancer Should indications for surgical resection be extended to intermediate hepatocellular carcinoma? Typically, surgical resection is offered only to patients with hepatocellular carcinomas of an early stage – called Barcelona Liver Cancer Clinic (BCLC) A. Here we adapted the BCLC classification system, showing that if you take the location of the tumour into account as well, you can cure some patients with more advanced BCLC B disease as well. Surgery can cure some patients with BCLC Sub class B1 cancers, if the cancer is confined to one lobe. It should be considered in these patients. Globally, hepatocellular carcinoma (HCC) represents the fourth most common cause of cancer-related mortality. 1 Surgical resection remains the main treatment modality in early HCC provided there is adequate liver function and sufficient future liver remnant. 2 A systematic review of 4209 patients with HCC within the Milan Criteria (MC) demonstrated median 5-year overall survival (OS) of 67% after surgical resection, which crosses 5-year OS of 50% thereby making surgical resection conceptually curative in this group of patients, 3 as first proposed by LLovet and Bruix in 1999 4 and in their subsequent update in 2002. 5 Recent evidence has however suggested that surgical resection may be justifiably offered to select individuals with intermediate- or advanced-stage disease. 6,7 While a number of staging systems have been validated for prognostic evaluation of HCC, there is no universally adopted system. Nevertheless, the Barcelon -Abstract Truncated-

Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines

Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification

Using machine learning to preoperatively stratify prognosis among patients with gallbladder cancer: a multi-institutional analysis

Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System

Machine learning models including preoperative and postoperative albumin-bilirubin score: short-term outcomes among patients with hepatocellular carcinoma

Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation

A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma.

Survival benefit of hepatic resection for hepatocellular carcinoma beyond the Barcelona Clinic Liver Cancer classification

Machine learning-based multimodal prediction of prognosis in patients with resected intrahepatic cholangiocarcinoma.

Preoperative identification of early extrahepatic recurrence after hepatectomy for colorectal liver metastases: A machine learning approach

Comparing Real World, Personalized, Multidisciplinary Tumor Board Recommendations with BCLC Algorithm: 321-Patient Analysis

A preoperative model to predict overall survival in patients with hepatoma undergoing resection

Combined measurements of tumor number and size helps estimate the outcome of resection of Barcelona clinic liver cancer stage B hepatocellular carcinoma

Clinical and Morpho-Molecular Classifiers for Prediction of Hepatocellular Carcinoma Prognosis and Recurrence after Surgical Resection.

Tumor burden score as a prognostic factor in patients with intermediate and locally advanced hepatocellular carcinoma undergoing liver resection: an attempt to extend resectability criteria

Prognostication algorithm for non-cirrhotic non-B non-C hepatocellular carcinoma—a multicenter study under the aegis of the French Association of Hepato-Biliary Surgery and liver Transplantation

Potential candidates for liver resection in liver-confined advanced HCC: a Chinese multicenter observational study

Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia

Machine learning model to predict early recurrence in patients with perihilar cholangiocarcinoma planned treatment with curative resection: a multicenter study

Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer

Data-Driven Assisted Decision Making for Surgical Procedure of Hepatocellular Carcinoma Resection and Prognostic Prediction: Development and Validation of Machine Learning Models